Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- Date of Movement: September 15, 2005
- Previous Holdings: 18,415,731 Ordinary Share ADRs
- New Holdings: 18,403,567 Ordinary Share ADRs
- Net Change: Decrease of 12,164 ADRs
- Average Price: $50.55
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the fund movement in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the 12,164 ADR reduction on the total beneficial ownership of the Plan.
- Confirm the specific nature of the "potential interest" held by Directors Dr. J P Garnier and Dr. T Yamada in the discretionary fund.
- Review the average transaction price of $50.55 against the market price of GSK ADRs on September 15, 2005.